Resmed Stock

Resmed EBITDA per Employee

The EBITDA per Employee of Resmed (RMD) as of Aug 4, 2026 is 239,038.12 USD. In the previous year, EBITDA per Employee was 188,731.22 USD — a change of 26.66% (higher).

EBITDA per Employee

239,038.12USD

YoY

26.66%

Last updated:

EBITDA per Employee of Resmed is 2026 239,038.12 USD. EBITDA per Employee of Resmed was 2025 188,731.22 USD. It decreases by 26.66% higher compared to the previous year.
Access this data via the Eulerpool API

Resmed Stock analysis

What does Resmed do? ResMed Inc. is a global leading provider of medical devices for the treatment of sleep disorders and respiratory diseases. The company was founded in Australia by Peter Farrell, a former employee of the University of New South Wales, in 1989. Today, ResMed is headquartered in San Diego, California, and employs over 7,500 people worldwide. Business model: ResMed's business model is based on providing medical products and solutions for the treatment of sleep apnea and other respiratory diseases. The company develops and distributes masks, devices, and accessories that help patients breathe better and achieve restful sleep. ResMed also offers cloud-based software solutions and services to assist doctors and sleep labs in diagnosing and monitoring patients. Products and divisions: ResMed's product range can be divided into four main divisions: Sleep & Respiratory Care, Software as a Service (SaaS), Technologies, and Dental Solutions. Sleep & Respiratory Care: In this division, ResMed offers a wide range of masks, devices, and accessories for the treatment of sleep apnea and other respiratory diseases. The most well-known products include the AirSense and AirMini devices, equipped with Automatic Sleep Detection and AutoSet algorithm to optimize respiratory pressure. ResMed also offers a range of CPAP masks, nasal and full face masks, as well as nasal pillow masks. Software as a Service (SaaS): ResMed's cloud-based software solutions and services are offered under the brand AirView. They include diagnostic tools, patient monitoring systems, and analysis tools. AirView allows doctors to access their patients' medical data captured by ResMed devices and monitor this data in real-time. Technologies: ResMed's Technologies division focuses on the development of advanced sensors for respiratory and sleep monitoring. Products include the S+, a smart sleep tracking system that operates without direct body contact, and the Reveal-LTE, an implant for monitoring heart and respiratory rates in patients with heart failure. Dental Solutions: ResMed has also developed products for dentistry to assist patients with mild to moderate upper airway obstruction. Products include the Narval CC, a custom-made dental device for the treatment of snoring and sleep apnea, and the Tap Pap nasal pillow oral appliance, a non-invasive mouthguard. Conclusion: ResMed is a leading provider of medical devices and solutions for the treatment of sleep apnea and other respiratory diseases. The company offers innovative products and technologies that help patients breathe better and achieve restful sleep. ResMed's cloud-based software solutions enable doctors to monitor their patients' health in real-time and develop effective diagnosis and treatment strategies. With its wide range of products, innovation, and highly qualified team of scientists, engineers, and medical professionals, ResMed will continue to play an important role in the healthcare industry. Resmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resmed stock

EBITDA per Employee of Resmed is 239,038.12 USD in 2026.

EBITDA per Employee of Resmed changed from 188,731.22 USD to 239,038.12 USD, representing a 26.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Resmed since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Resmed historically and in real time.

Access this data via the Eulerpool API

Workforce — Resmed

All Key Metrics — Resmed